

Claims

1. Use of an immunoconjugate that binds to folate receptor 1 (FOLR1) for the manufacture of a medicament for treating cancer in a patient in need thereof, wherein said immunoconjugate comprises (i) an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:9, a VH CDR2 sequence of SEQ ID NO:10, and a VH CDR3 sequence of SEQ ID NO:12, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:6, a VL CDR2 sequence of SEQ ID NO:7, and a VL CDR3 sequence of SEQ ID NO:8, and (ii) a maytansinoid, wherein the maytansinoid is linked to the antibody or antigen-binding fragment thereof by sulfo-SPDB, and

wherein the medicament is for use in combination with an anti-VEGF agent, a platinum-based agent, or doxorubicin.

2. The use of claim 1, wherein the immunoconjugate is for administration in combination with the anti-VEGF agent.

3. The use of claim 1, wherein the immunoconjugate is for administration in combination with the platinum-based agent.

4. The use of claim 1, wherein the immunoconjugate is for administration in combination with the doxorubicin.

5. Use of an immunoconjugate that binds to folate receptor 1 (FOLR1) for the manufacture of a medicament for treating cancer in a patient in need thereof, wherein said immunoconjugate comprises (i) an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:9, a VH CDR2 sequence of SEQ ID NO:10, and a VH CDR3 sequence of SEQ ID NO:12, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:6, a VL CDR2 sequence of SEQ ID NO:7, and a VL CDR3 sequence of SEQ ID NO:8, and (ii) a maytansinoid, wherein the maytansinoid is linked to the antibody or antigen-binding fragment thereof by sulfo-SPDB, and

wherein the medicament is for use in combination with

- (i) an anti-VEGF agent and a platinum-based agent;
- (ii) an anti-VEGF agent and doxorubicin; or

(iii) a platinum-based agent and doxorubicin.

6. The use of any one of claims 1, 2, and 5, wherein the anti-VEGF agent is bevacizumab.
7. The use of any one of claims 1, 3, 5, and 6, wherein the platinum-based agent is carboplatin.
8. The use of claim 1, 4, or 5, wherein the doxorubicin is pegylated liposomal doxorubicin (PLD).
9. The use of any one of claims 1-8, wherein the immunoconjugate that binds to FOLR1 comprises an antibody or antigen-binding fragment thereof that comprises a VH comprising the sequence of SEQ ID NO:3 and a VL comprising the sequence of SEQ ID NO:5.
10. The use of any one of claims 1-9, wherein the immunoconjugate comprises an antibody comprising (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:13 and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 15, and wherein the maytansinoid is DM4.
11. The use of any one of claims 1-10, wherein the immunoconjugate comprises an antibody comprising (i) a heavy chain comprising the same amino acid sequence as the amino acid sequence of the heavy chain encoded by the plasmid deposited with the American Type Culture Collection (ATCC) as PTA-10772 and (ii) a light chain comprising the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited with the ATCC as PTA-10774, and wherein the maytansinoid is DM4.
12. The use of any one of claims 1-10, wherein the maytansinoid is DM4.
13. The use of any one of claims 1-12, wherein the immunoconjugate is for administration once every three weeks at a dose of 6 mg/kg adjusted ideal body weight (AIBW).
14. The use of any one of claims 1-12, wherein the immunoconjugate is for administration once every four weeks at a dose of 5 mg/kg AIBW or once every four weeks at a dose of 6 mg/kg AIBW.

15. The use of any one of claims 6, 7, or 9-13, wherein the bevacizumab is for administration once every three weeks at a dose of 15 mg/kg.
16. The use of any one of claims 6, 7, or 9-13, wherein the bevacizumab is for administration twice every four weeks at a dose of 10 mg/kg.
17. The use of any one of claims 7 or 9-13, wherein the carboplatin is for administration once every three weeks at a dose to obtain an area under the curve (AUC) of 5 mg/ml min or 6 mg/ml min.
18. The use of any one of claims 8-14, wherein the PLD is for administration once every four weeks at a dose of 40 mg/m² or once every four weeks at a dose of 30 mg/m².
19. The use of any one of claims 1-18, wherein the the immunoconjugate comprises from about 1 maytansinoid per antibody to about 8 maytansinoids per antibody, optionally wherein the immunoconjugate comprises from about 3 maytansinoids per antibody to about 4 maytansinoids per antibody.
20. The use of any one of claims 1-19, which further wherein the medicament is for administration of a steroid to the patient, wherein the steroid is administered as an eye drop.
21. The use of any one of claims 1-20, wherein the cancer is ovarian, peritoneal, fallopian, endometrial, or lung cancer.
22. The use of claim 21, wherein the cancer is ovarian cancer, peritoneal cancer, or endometrial cancer, optionally wherein the ovarian cancer is platinum-resistant epithelial ovarian cancer.
23. The use of any one of claims 1-22, wherein the cancer expresses FOLR1.
24. The use of claim 23, wherein the FOLR1 expression is measured by immunohistochemistry (IHC).
25. The use of claim 24, wherein at least 25% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 2.

26. The use of claim 24, wherein at least 50% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 2.
27. The use of claim 24, wherein at least 75% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 2.
28. The use of claim 24, wherein 25%-75% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 2.
29. The use of claim 24, wherein at least 50% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 3.
30. The use of claim 24, wherein at least 75% of cells in a sample obtained from the patient have an immunohistochemistry (IHC) score of at least 3.
31. The use of any one of claims 1-30, wherein the immunoconjugate and the anti-VEGF agent; platinum-based agent; doxorubicin; anti-VEGF agent and platinum-based agent; anti-VEGF agent and doxorubicin; or platinum-based agent and doxorubicin are administered in separate pharmaceutical compositions.
32. The use of any one of claims 1-31, wherein the cancer has previously been treated with bevacuzimab.
33. The use of any one of claims 1-31, wherein the cancer has not previously been treated with bevacuzimab.
34. The use of any one of claims 1-33, wherein the cancer is primary platinum refractory.
35. The use of any one of claims 1-33, wherein the cancer is platinum resistant.
36. The use of any one of claims 1-33, wherein the cancer is platinum sensitive.
37. The use of any one of claims 1-31 or 33-36, wherein the medicament is for administration as a first-line therapy.

38. The use of any one of claims 1-36 wherein the medicament is for administration as a second-line therapy.
39. The use of any one of claims 1-36, wherein the medicament is for administration as a third-line therapy.
40. The use of any one of claims 1-36, wherein the administration is a fourth-line therapy.
41. The use of any one of claims 1-36, wherein the administration is a fifth-line therapy.